|
Accueil > Actualité
AstraZeneca: Alexion completes deal with Pfizer
(CercleFinance.com) - AstraZeneca's rare disease subsidiary Alexion announced on Wednesday that it has completed the acquisition of the gene therapy business of US-based Pfizer, a deal valued at close to $1bn.
Initially announced at the end of July, this acquisition will enable Alexion and AstraZeneca to strengthen their capabilities in genomic medicine, aiming to develop new targeted therapies. Several Pfizer employees are expected to join Alexion's teams as part of the deal. The transaction's reference price of $1bn does not take into account future royalties on drugs that could potentially be commercialised as a result of the agreement. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
11/12/2023 10:41
Bristol Myersrésultats positifs autour du Breyanzi 11/12/2023 10:30 Rochede nouvelles données positives au congrès ASH 11/12/2023 10:20 Holcimreçoit deux prix lors de la COP28 11/12/2023 10:10 Pharnextle titre chute après une étude clinique décevante 11/12/2023 10:03 Forsee Powertirage d'une tranche auprès de la BEI 11/12/2023 09:51 Alstoma inauguré le tram-train Citadis Dualis en Essonne Tous les articles sociétés |
